Streetbeat News

Price Targets

LBPH

Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Longboard Pharmaceuticals and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:54 pm

KRTX

Cantor Fitzgerald analyst Charles Duncan has reiterated a Neutral rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $214.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:53 pm

KALV

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on KalVista Pharma (NASDAQ:KALV) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:52 pm

JAZZ

Cantor Fitzgerald analyst Brandon Folkes has reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $180.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:50 pm

ITCI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $98 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:50 pm

SKT

B of A Securities analyst Craig Schmidt maintains an 'Underperform' rating on Tanger Factory Outlet (NYSE:SKT) and raises the price target from $18.5 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:49 pm

REG

B of A Securities analyst Jeffrey Spector maintains a 'Buy' rating on Regency Centers (NASDAQ:REG) but lowers the price target from $79 to $74.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:48 pm

KRG

B of A Securities analyst Craig Schmidt maintains a Buy rating on Kite Realty Gr Trust (NYSE:KRG) and raises the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:46 pm

HRMY

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:45 pm

FRT

B of A Securities analyst Jeffrey Spector maintains a Buy rating on Federal Realty Investment (NYSE:FRT) but lowers the price target from $125 to $124.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:45 pm